keyword
MENU ▼
Read by QxMD icon Read
search

Roger McIntyre

keyword
https://www.readbyqxmd.com/read/28296941/the-association-between-methylphenidate-treatment-and-the-risk-for-fracture-among-young-adhd-patients-a-nationwide-population-based-study-in-taiwan
#1
Vincent Chin-Hung Chen, Yao-Hsu Yang, Yin-To Liao, Ting-Yu Kuo, Hsin-Yi Liang, Kuo-You Huang, Yin-Cheng Huang, Yena Lee, Roger S McIntyre, Tzu-Chin Lin
Attention-deficit hyperactivity disorder (ADHD) is associated with higher risk for fracture. Whether the medical treatment for ADHD would mitigate the risk remains unclear. In this study, we sought to investigate the effect of methylphenidate treatment on risk for fracture, as well the moderational role of treatment duration on the risk of fracture, in a large national sample. Cases less than 18 years old were identified from Taiwan's National Health Insurance Research Database with a new primary diagnosis of ADHD (ICD-9:314) between 1996 and 2013...
2017: PloS One
https://www.readbyqxmd.com/read/28264727/mixed-features-and-mixed-states-in-psychiatry-from-calculus-to-geometry
#2
Roger S McIntyre
No abstract text is available yet for this article.
March 7, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28257449/effects-of-selective-serotonin-reuptake-inhibitors-on-glaucoma-a-nationwide-population-based-study
#3
Vincent Chin-Hung Chen, Mei-Hing Ng, Wei-Che Chiu, Roger S McIntyre, Yena Lee, Tsang-Yaw Lin, Jun-Cheng Weng, Pau-Chung Chen, Chung-Yao Hsu
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are one of the most commonly prescribed classes of antidepressants. Glaucoma is the second leading cause of blindness globally and iatrogenic glaucoma has been implicated across disparate medication classes. Available studies that have sought to determine the association between SSRI exposure and glaucoma have provided mixed results. The aim of the study herein was to investigate whether an association exists between SSRI exposure and glaucoma incidence...
2017: PloS One
https://www.readbyqxmd.com/read/28213943/a-phase-2-safety-study-of-accelerated-elotuzumab-infusion-over-less-than-1-hour-in-combination-with-lenalidomide-and-dexamethasone-in-patients-with-multiple-myeloma
#4
James Berenson, Robert Manges, Suprith Badarinath, Alan Cartmell, Kristi McIntyre, Roger Lyons, Wael Harb, Hesham Mohamed, Ali Nourbakhsh, Robert Rifkin
Elotuzumab, an immunostimulatory SLAMF7-targeting monoclonal antibody, induces myeloma cell death with minimal effects on normal tissue. In a previous phase 3 study in patients with relapsed/refractory multiple myeloma (RRMM), elotuzumab (10 mg/kg, ∼3-hour infusion), combined with lenalidomide and dexamethasone, demonstrated durable efficacy and acceptable safety; 10% (33/321) of patients had infusion reactions (IRs; Grade 1/2: 29; Grade 3: 4). This phase 2 study (NCT02159365) investigated an accelerated infusion schedule in 70 patients with newly diagnosed multiple myeloma or RRMM...
February 18, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28107669/medical-comorbidity-in-bipolar-disorder-the-link-with-metabolic-inflammatory-systems
#5
REVIEW
Ana SayuriYamagata, Elisa Brietzke, Joshua D Rosenblat, Ron Kakar, Roger S McIntyre
BACKGROUND: Bipolar disorder (BD) is associated with chronic low-grade inflammation, several medical comorbidities and a decreased life expectancy. Metabolic-inflammatory changes have been postulated as one of the main links between BD and medical comorbidity, although there are few studies exploring possible mechanisms underlying this relationship. Therefore, the aims of the current narrative review were 1) synthesize the evidence for metabolic-inflammatory changes that may facilitate the link between medical comorbidity and BD and 2) discuss therapeutic and preventive implications of these pathways...
March 15, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28078987/role-of-proinflammatory-cytokines-in-dopaminergic-system-disturbances-implications-for-anhedonic-features-of-mdd
#6
Zihang Pan, Joshua D Rosenblat, Walter Swardfager, Roger S McIntyre
Anhedonia, characterized by a loss of interest and/or pleasure in previously enjoyable activities, is an important diagnostic criterion of Major Depressive Disorder (MDD). Converging evidence implicates a behaviouralcausal relationship between proinflammatory cytokines and disturbances that characterize anhedonia in the context of MDD. Additionally, anhedonia has been implicated in disturbances of key central dopaminergic modulatory pathways. Emerging research into the roles of tetrahydrobiopterin, a cytokine-targeted co-enzyme in the synthesis of dopamine, and kynurenine, a product of inflammation-sensitive breakdown of tryptophan via indoleamine 2, 3-dioxygenase, have shed new light into the role of inflammation in mediating anhedonic behaviours...
January 11, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28073041/major-depressive-disorder-with-subthreshold-hypomanic-mixed-features-a-real-world-assessment-of-treatment-patterns-and-economic-burden
#7
Roger S McIntyre, Daisy Ng-Mak, Chien-Chia Chuang, Rachel Halpern, Pankaj A Patel, Krithika Rajagopalan, Antony Loebel
BACKGROUND: To compare outcomes for individuals with major depressive disorder (MDD) with or without subthreshold hypomania (mixed features) in naturalistic settings. METHODS: Using the Optum Research Database (1/1/2009─10/31/2014), a retrospective analysis of individuals newly diagnosed with MDD was conducted. Continuous enrollment for 12-months before and after the initial MDD diagnosis was required. MDD with subthreshold hypomania (mixed features) (MDD-MF) was defined based on ≥1 hypomania diagnosis within 30 days after an MDD diagnosis during the one-year follow-up period, in the absence of bipolar I diagnoses...
March 1, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28068459/does-pharmacogenomic-testing-improve-clinical-outcomes-for-major-depressive-disorder-a-systematic-review-of-clinical-trials-and-cost-effectiveness-studies
#8
Joshua D Rosenblat, Yena Lee, Roger S McIntyre
OBJECTIVE: Pharmacogenomic testing has become scalable and available to the general public. Pharmacogenomics has shown promise for predicting antidepressant response and tolerability in the treatment of major depressive disorder (MDD). In theory, pharmacogenomics can improve clinical outcomes by guiding antidepressant selection and dosing. The current systematic review examines the extant literature to determine the impact of pharmacogenomic testing on clinical outcomes in MDD and assesses its cost-effectiveness...
January 3, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28044944/a-pragmatic-approach-to-the-diagnosis-and-treatment-of-mixed-features-in-adults-with-mood-disorders
#9
Roger S McIntyre, Yena Lee, Rodrigo B Mansur
Mixed features specifier (MFS) is a new nosological entity defined and operationalized in the Diagnostic and Statistical Manual of Mental Disorders (DSM), 5th Edition. The impetus to introduce the MFS and supplant mixed states was protean, including the lack of ecological validity, high rates of misdiagnosis, and guideline discordant treatment for mixed states. Mixed features specifier identifies a phenotype in psychiatry with greater illness burden, as evidenced by earlier age at onset, higher episode frequency and chronicity, psychiatric and medical comorbidity, suicidality, and suboptimal response to conventional antidepressants...
December 2016: CNS Spectrums
https://www.readbyqxmd.com/read/28013123/a-randomized-double-blind-placebo-controlled-crossover-trial-evaluating-the-effect-of-intranasal-insulin-on-cognition-and-mood-in-individuals-with-treatment-resistant-major-depressive-disorder
#10
Danielle S Cha, Michael W Best, Christopher R Bowie, Laura Ashley Gallaugher, Hanna O Woldeyohannes, Joanna K Soczynska, Gary Lewis, Glenda MacQueen, Barbara J Sahakian, Sidney H Kennedy, Jane P Lui, Rodrigo B Mansur, Roger S McIntyre
BACKGROUND: Cognitive dysfunction in major depressive disorder (MDD) is identified as a primary therapeutic target; no current treatment is approved for the treatment of cognitive dysfunction in MDD. We examined whether intranasal insulin offered a beneficial effect across measures of cognitive function in adults with MDD. METHODS: Thirty-five adults (18-65 years of age: 47.09±9.89) meeting criteria for a major depressive episode as per the Diagnostic and Statistical Manual (DSM)-IV-Treatment Revised were included in this randomized, double blind, placebo-controlled, crossover design study...
March 1, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/27935809/assessing-and-measuring-cognitive-function-in-major-depressive-disorder
#11
Renee-Marie Ragguett, Danielle S Cha, Ron Kakar, Joshua D Rosenblat, Yena Lee, Roger S McIntyre
Cognitive dysfunction is a major component of major depressive disorder (MDD). No 'gold-standard' tool exists for the assessment of cognitive dysfunction for adults with MDD. The use of measurement-based care to improve treatment outcomes invites the need for a systematic screening, evaluation and measurement tool. The aim herein was to provide a succinct summary of literature documenting clinical implication of cognitive dysfunction in MDD, and a review of available screening, diagnostic and measurement tools for cognitive dysfunction in MDD is provided...
November 2016: Evidence-based Mental Health
https://www.readbyqxmd.com/read/27913990/sirukumab-a-potential-treatment-for-mood-disorders
#12
REVIEW
Aileen J Zhou, Yena Lee, Giacomo Salvadore, Benjamin Hsu, Trehani M Fonseka, Sidney H Kennedy, Roger S McIntyre
Convergent evidence indicates that abnormalities in the innate immune system may be pertinent to the pathogenesis, phenomenology, and possible treatment of several mental disorders. In keeping with this view, the targeting of interleukin-6 with the human monoclonal antibody sirukumab may represent a possible treatment and disease modification approach, for adults with brain-based disorders (e.g., major depressive disorder). A PubMed/Medline database search was performed using the following search terms: sirukumab; anti-IL-6; IL-6; major depressive disorder; inflammation...
January 2017: Advances in Therapy
https://www.readbyqxmd.com/read/27884012/gut-microbiota-bacterial-translocation-and-interactions-with-diet-pathophysiological-links-between-major-depressive-disorder-and-non-communicable-medical-comorbidities
#13
Anastasiya Slyepchenko, Michael Maes, Felice N Jacka, Cristiano A Köhler, Tatiana Barichello, Roger S McIntyre, Michael Berk, Iria Grande, Jane A Foster, Eduard Vieta, André F Carvalho
BACKGROUND: Persistent low-grade immune-inflammatory processes, oxidative and nitrosative stress (O&NS), and hypothalamic-pituitary-adrenal axis activation are integral to the pathophysiology of major depressive disorder (MDD). The microbiome, intestinal compositional changes, and resultant bacterial translocation add a new element to the bidirectional interactions of the gut-brain axis; new evidence implicates these pathways in the patho-aetiology of MDD. In addition, abnormalities in the gut-brain axis are associated with several chronic non-communicable disorders, which frequently co-occur in individuals with MDD, including but not limited to irritable bowel syndrome (IBS), chronic fatigue syndrome (CFS), obesity, and type 2 diabetes mellitus (T2DM)...
2017: Psychotherapy and Psychosomatics
https://www.readbyqxmd.com/read/27871787/selfish-brain-and-selfish-immune-system-interplay-a-theoretical-framework-for-metabolic-comorbidities-of-mood-disorders
#14
REVIEW
Ana Sayuri Yamagata, Rodrigo Barbachan Mansur, Lucas Bortolotto Rizzo, Tatiana Rosenstock, Roger S McIntyre, Elisa Brietzke
According to the "selfish brain" theory, the brain regulates its own energy supply influencing the peripheral metabolism and food intake according to its needs. The immune system has been likewise "selfish" due to independent energy consumption; and it may compete with the brain (another high energy-consumer) for glucose. In mood disorders, stress in mood episodes or physiological stress activate homeostasis mechanisms from the brain and the immune system to solve the imbalance. The interaction between the selfish brain and the selfish immune system may explain various conditions of medical impairment in mood disorders, such as Metabolic Syndrome (MetS), obesity, type 2 diabetes mellitus (T2DM) and immune dysregulation...
January 2017: Neuroscience and Biobehavioral Reviews
https://www.readbyqxmd.com/read/27861191/effects-of-levomilnacipran-extended-release-on-major-depressive-disorder-patients-with-cognitive-impairments-post-hoc-analysis-of-a-phase-iii-study
#15
Keith A Wesnes, Carl Gommoll, Changzheng Chen, Angelo Sambunaris, Roger S McIntyre, Philip D Harvey
Performance-based cognitive data were collected using the Cognitive Drug Research System in a study of levomilnacipran extended-release (ER) 40-120 mg/day (NCT01034462) in adults with major depressive disorder. These data were analyzed post-hoc to explore the relationship between cognitive measures, depression symptoms (Montgomery-Åsberg Depression Rating Scale, MADRS), and self-reported psychosocial functioning (Sheehan Disability Scale; SDS). Changes from baseline were analyzed in the intent-to-treat population and subgroups with impaired attention, as indicated by baseline Cognitive Drug Research System scores for Power of Attention and Continuity of Attention...
March 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27835721/functional-recovery-in-major-depressive-disorder-focus-on-early-optimized-treatment
#16
Jeffrey Habert, Martin A Katzman, Oloruntoba J Oluboka, Roger S McIntyre, Diane McIntosh, Glenda M MacQueen, Atul Khullar, Roumen V Milev, Kevin D Kjernisted, Pratap R Chokka, Sidney H Kennedy
Objective: This article presents the case that a more rapid, individualized approach to treating major depressive disorder (MDD) may increase the likelihood of achieving full symptomatic and functional recovery for individual patients and that studies show it is possible to make earlier decisions about appropriateness of treatment in order to rapidly optimize that treatment. Data Sources: A PubMed search was conducted using terms including major depressive disorder, early improvement, predictor, duration of untreated illness, and function...
September 1, 2016: Primary Care Companion to CNS Disorders
https://www.readbyqxmd.com/read/27821210/asenapine-for-the-treatment-of-adults-with-an-acute-exacerbation-of-schizophrenia-results-from-a-randomized-double-blind-fixed-dose-placebo-controlled-trial-with-olanzapine-as-an-active-control
#17
Ronald Landbloom, Mary Mackle, Xiao Wu, Linda Kelly, Linda Snow-Adami, Roger S McIntyre, Maju Mathews, Carla Hundt
OBJECTIVE: Evaluate the efficacy and safety of asenapine 2.5 mg twice daily (bid; n=97) or 5 mg bid (n=113) versus placebo (n=101) in adults with acute exacerbation of schizophrenia. METHODS: Adults with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) schizophrenia diagnosis were randomized to asenapine 2.5 mg bid, 5 mg bid, placebo, or olanzapine 15 mg once daily. The primary objective was to test superiority of asenapine versus placebo as measured by the change from baseline to day 42 in the Positive and Negative Syndrome Scale (PANSS) total score...
November 8, 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27810270/the-association-between-insulin-resistance-and-depression-in-the-korean-general-population
#18
Jae-Hon Lee, Sung Keun Park, Jae-Hong Ryoo, Chang-Mo Oh, Rodrigo B Mansur, Jeffrey E Alfonsi, Danielle S Cha, Yena Lee, Roger S McIntyre, Ju Young Jung
BACKGROUND: Previous studies showed that the insulin resistance (IR) could be related to depression. However, this association is still equivocal in the general population. Herein, we aimed to investigate the association between IR and depressive symptoms in a large sample in South Korea. METHODS: A cross-sectional study was carried out for 165,443 Korean men and women who received a health checkup including various clinical parameters and the Center for Epidemiologic Studies Depression scales (CES-D)...
January 15, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/27788319/implementing-appropriate-treatment-strategies-for-varying-types-of-depression
#19
Roger S McIntyre
Reassessing a patient's diagnosis if he or she does not respond adequately to initial antidepressant pharmacotherapy is imperative. In this CME activity, evaluate the case of Melissa, a 32-year-old architect with a potential case of treatment-resistant depression, and decide on appropriate treatment strategies.
October 2016: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/27783998/hepatocellular-carcinoma-and-antidepressants-a-nationwide-population-based-study
#20
Vincent Chin-Hung Chen, Chiao-Fan Lin, Yi-Hsuan Hsieh, Hsin-Yi Liang, Kuo-You Huang, Wei-Che Chiu, Yena Lee, Roger S McIntyre, Hsiang-Lin Chan
Hepatocellular carcinoma (HCC) is highly prevalent in Asia. Antidepressants have been associated with increase in hepatocellular carcinoma. This is the first Asian population-based study to evaluate the association between antidepressant use and risk of HCC. Based on Taiwan's National Health Insurance Research Database, we conducted a nationwide population-based study. A total of 49,998 cases with HCC were identified and paired with 244,236 randomly selected controls. The data was analyzed via the conditional logistic regression model adjusting for several confounding factors...
October 23, 2016: Oncotarget
keyword
keyword
44509
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"